Key Insights

Highlights

Treatment Research

1 treatments under study, led by Switch Of Anti Tnf For Ustekinumab For Paradoxical Psoriasis

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Not Applicable (1)

Trial Status

Unknown1
Recruiting1

Clinical Trials (2)

Showing 2 of 2 trials
NCT07529236Not ApplicableRecruitingPrimary

Digestive Evolution of Children With Crohn's Disease or Ulcerative Colitis Whose Anti-TNFα Treatment Was Switched to Ustekinumab Due to Paradoxical Psoriasis,

NCT06214299UnknownPrimary

Study of the Psychometric Properties of Two Questionnaires for Measuring Disease Flare-up in IBD

Showing all 2 trials

Research Network

Common Treatments

  • Switch Of Anti Tnf For Ustekinumab For Paradoxical Psoriasis1

Active Sponsors

  • EPSTEIN Jonathan1
  • Centre Hospitalier Universitaire de Nice1

Top Investigators

Activity Timeline